Systematic review and meta-analysis of the efficacy of clinically tested protectants of cisplatin nephrotoxicity
Cisplatin is a potent antineoplastic drug that has been widely used to treat a number of solid tumors. However, a high incidence of renal damage observed in patients has led researchers to search for alternate strategies that prevent or at least reduce the cisplatin-induced nephrotoxicity. The objective of the present study was to conduct a systematic review and a subsequent meta-analysis to evaluate and identify compounds with effective antitumor activity and lesser side effects that could provide protection against cisplatin-induced nephrotoxicity.
The study included all placebo-controlled trials published up to December 2017 that met the inclusion criteria. A total of 22 articles were finally included to extract the following information: number of patients, doses of cisplatin and protectant, qualitative (acute kidney injury incidence) and quantitative (plasma creatinine, blood urea nitrogen, and creatinine clearance) indicators of renal function. The odds ratio or the mean difference (95% confidence interval) of each parameter was calculated for each study and group of studies.
The results of this meta-analysis show that there is great variability in the nephroprotective capacity of a variety of products evaluated. Of all the compounds tested, only magnesium sulfate and cystone were found to exert protective effects. However, more studies need to be conducted to confirm these results.
The administration of 1 g of Mg i.v. seems to be the best strategy for the prevention of cisplatin nephrotoxicity.
KeywordsNephroprotection Cisplatin Meta-analysis Clinical Magnesium Cystone
M. Teresa Hernández-Sánchez is a recipient of a predoctoral fellowship from the Junta de Castilla y León (Spain) and the European Social Fund from the European Commission. Research from the authors’ laboratory supporting part of the information incorporated into this article has been funded by grants from Instituto de Salud Carlos III (PI17/01979, DT15S/00166, and PI15/01055, PI14/01776), co-funded by FEDER, and Retic (RD016/0009/0025) REDINREN-FEDER funds, Junta de Castilla y León, Consejería de Sanidad (BIO/SA66/15, BIO/SA20/14); and Consejería de Educación, (SA359U14).
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 3.Cameron LK, Lei K, Smith S, Doyle NL, Doyle JF, Flynn K, Purchase N, Smith J, Chan K, Kamara F, Kidane NG, Forni LG, Harrington D, Hampson G, Ostermann M (2017) Vitamin D levels in critically ill patients with acute kidney injury: a protocol for a prospective cohort study (VID-AKI). BMJ Open 7:e016486. https://doi.org/10.1136/bmjopen-2017-016486 CrossRefPubMedPubMedCentralGoogle Scholar
- 4.Susantitaphong P, Cruz DN, Cerda J, Abulfaraj M, Alqahtani F, Koulouridis I, Jaber BL, Acute Kidney Injury Advisory Group of the American Society of Nephrology (2013) World incidence of AKI: a meta-analysis. Clin J Am Soc Nephrol CJASN 8:1482–1493. https://doi.org/10.2215/CJN.00710113 CrossRefPubMedGoogle Scholar
- 14.Marullo R, Werner E, Degtyareva N, Moore B, Altavilla G, Ramalingam SS, Doetsch PW (2013) Cisplatin induces a mitochondrial-ROS response that contributes to cytotoxicity depending on mitochondrial redox status and bioenergetic functions. PLoS One 8:e81162. https://doi.org/10.1371/journal.pone.0081162 CrossRefPubMedPubMedCentralGoogle Scholar
- 23.Sancho-Martínez SM, Prieto-García L, Prieto M, Fuentes-Calvo I, López-Novoa JM, Morales AI, Martínez-Salgado C, López-Hernández FJ (2018) N-acetylcysteine transforms necrosis into apoptosis and affords tailored protection from cisplatin cytotoxicity. Toxicol Appl Pharmacol 349:83–93. https://doi.org/10.1016/j.taap.2018.04.010 CrossRefPubMedGoogle Scholar
- 24.Hayati F, Hossainzadeh M, Shayanpour S et al (2015) Prevention of cisplatin nephrotoxicity. J Nephropharmacology 5:57–60Google Scholar
- 28.Benoehr P, Krueth P, Bokemeyer C, Grenz A, Osswald H, Hartmann JT (2005) Nephroprotection by theophylline in patients with cisplatin chemotherapy: a randomized, single-blinded, placebo-controlled trial. J Am Soc Nephrol JASN 16:452–458. https://doi.org/10.1681/ASN.2004030225 CrossRefPubMedGoogle Scholar
- 29.Bodnar L, Wcislo G, Gasowska-Bodnar A et al (2008) Renal protection with magnesium subcarbonate and magnesium sulphate in patients with epithelial ovarian cancer after cisplatin and paclitaxel chemotherapy: a randomised phase II study. Eur J Cancer Oxf Engl 1990 44:2608–2614. https://doi.org/10.1016/j.ejca.2008.08.005 CrossRefGoogle Scholar
- 30.El-Ghiaty MA, Ibrahim OMH, Abdou SM, Hussein FZ (2014) Evaluation of the protective effect of cystone against cisplatin-induced nephrotoxicity in cancer patients, and its influence on cisplatin antitumor activity. Int Urol Nephrol 46:1367–1373. https://doi.org/10.1007/s11255-014-0644-y CrossRefPubMedGoogle Scholar
- 33.Ikemura K, Oshima K, Enokiya T, Okamoto A, Oda H, Mizuno T, Ishinaga H, Muraki Y, Iwamoto T, Takeuchi K, Katayama N, Okuda M (2017) Co-administration of proton pump inhibitors ameliorates nephrotoxicity in patients receiving chemotherapy with cisplatin and fluorouracil: a retrospective cohort study. Cancer Chemother Pharmacol 79:943–949. https://doi.org/10.1007/s00280-017-3296-7 CrossRefPubMedGoogle Scholar
- 35.Kidera Y, Kawakami H, Sakiyama T, Okamoto K, Tanaka K, Takeda M, Kaneda H, Nishina S, Tsurutani J, Fujiwara K, Nomura M, Yamazoe Y, Chiba Y, Nishida S, Tamura T, Nakagawa K (2014) Risk factors for cisplatin-induced nephrotoxicity and potential of magnesium supplementation for renal protection. PLoS One 9:e101902. https://doi.org/10.1371/journal.pone.0101902 CrossRefPubMedPubMedCentralGoogle Scholar
- 36.Konishi H, Fujiwara H, Itoh H et al (2017) Influence of magnesium and parathyroid hormone on cisplatin-induced nephrotoxicity in esophageal squamous cell carcinoma. Oncol Lett. https://doi.org/10.3892/ol.2017.7345
- 38.Matsui M, Saito Y, Yamaoka S, et al (2018) Kidney-protective effect of magnesium supplementation in cisplatin-containing chemotherapy for pediatric cancer: a retrospective study. J Pediatr Hematol Oncol 1. https://doi.org/10.1097/MPH.0000000000001159
- 39.McKibbin T, Cheng LL, Kim S, Steuer CE, Owonikoko TK, Khuri FR, Shin DM, Saba NF (2016) Mannitol to prevent cisplatin-induced nephrotoxicity in patients with squamous cell cancer of the head and neck (SCCHN) receiving concurrent therapy. Support Care Cancer Off J Multinatl Assoc Support Care Cancer 24:1789–1793. https://doi.org/10.1007/s00520-015-2978-0 CrossRefGoogle Scholar
- 42.Osama H, Abdullah A, Gamal B, Emad D, Sayed D, Hussein E, Mahfouz E, Tharwat J, Sayed S, Medhat S, Bahaa T, Abdelrahim MEA (2017) Effect of honey and royal jelly against cisplatin-induced nephrotoxicity in patients with cancer. J Am Coll Nutr 36:342–346. https://doi.org/10.1080/07315724.2017.1292157 CrossRefPubMedGoogle Scholar
- 43.Saito Y, Kobayashi M, Yamada T, Kasashi K, Honma R, Takeuchi S, Shimizu Y, Kinoshita I, Dosaka-Akita H, Iseki K (2017) Premedication with intravenous magnesium has a protective effect against cisplatin-induced nephrotoxicity. Support Care Cancer Off J Multinatl Assoc Support Care Cancer 25:481–487. https://doi.org/10.1007/s00520-016-3426-5 CrossRefGoogle Scholar
- 45.Shahbazi F, Sadighi S, Dashti-Khavidaki S, Shahi F, Mirzania M, Abdollahi A, Ghahremani MH (2015) Effect of silymarin administration on cisplatin nephrotoxicity: report from a pilot, randomized, double-blinded, placebo-controlled clinical trial. Phytother Res PTR 29:1046–1053. https://doi.org/10.1002/ptr.5345 CrossRefPubMedGoogle Scholar
- 46.Uozumi J, Koikawa Y, Yasumasu T et al (1996) The protective effect of methylprednisolone against cisplatin-induced nephrotoxicity in patients with urothelial tumors. Int J Urol Off J Jpn Urol Assoc 3:343–347Google Scholar
- 47.Weijl NI, Elsendoorn TJ, Lentjes EGWM et al (1990) (2004) Supplementation with antioxidant micronutrients and chemotherapy-induced toxicity in cancer patients treated with cisplatin-based chemotherapy: a randomised, double-blind, placebo-controlled study. Eur J Cancer Oxf Engl 40:1713–1723. https://doi.org/10.1016/j.ejca.2004.02.029 CrossRefGoogle Scholar
- 48.Yanagimoto Y, Takiguchi S, Miyazaki Y, Makino T, Takahashi T, Kurokawa Y, Yamasaki M, Miyata H, Nakajima K, Hosoda H, Kangawa K, Mori M, Doki Y (2016) Improvement of cisplatin-related renal dysfunction by synthetic ghrelin: a prospective randomised phase II trial. Br J Cancer 114:1318–1325. https://doi.org/10.1038/bjc.2016.160 CrossRefPubMedPubMedCentralGoogle Scholar
- 53.Chintala V, Prabhu VM, Boyanagari M, Bhat AN (2018) Role of hypomagnesaemia in acute kidney injury. J Clin Diagn Res. https://doi.org/10.7860/JCDR/2018/28073.11329
- 54.Bussière FI, Gueux E, Rock E, Girardeau JP, Tridon A, Mazur A, Rayssiguier Y (2002) Increased phagocytosis and production of reactive oxygen species by neutrophils during magnesium deficiency in rats and inhibition by high magnesium concentration. Br J Nutr 87:107–113. https://doi.org/10.1079/BJN2001498 CrossRefPubMedGoogle Scholar